Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, featuring one oral and two poster sessions. The data highlight the potential of TNX-1700 and TNX-4700 in cancer treatment, with TNX-1700 showing reduced inflammation and tumor progression in gastric cancer models, and TNX-4700 demonstrating promising in vitro activity targeting BTLA, a checkpoint receptor.
TNX-1700 is a novel biologic designed to modulate the tumor microenvironment. In preclinical gastric cancer models, TNX-1700 reduced inflammation and tumor progression, while also showing favorable pharmacokinetics. These findings support its continued development as a potential therapy for gastric cancer, a disease with high unmet medical need.
TNX-4700 is a monoclonal antibody that targets BTLA (B- and T-lymphocyte attenuator), an immune checkpoint receptor. In vitro studies showed that TNX-4700 enhances T-cell activation, suggesting its potential as a monotherapy or in combination with other checkpoint inhibitors. This approach could expand the landscape of cancer immunotherapy by targeting alternative immune checkpoints.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. The company's CNS portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), recently approved for fibromyalgia, and other products for migraine and potential treatments for major depressive disorder and acute stress disorder. In immunology, Tonix is advancing monoclonal antibodies for Lyme disease prophylaxis and transplant rejection prevention.
The presentation of these data at AACR 2026 underscores Tonix's commitment to developing innovative cancer therapies. For more information about Tonix and its pipeline, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/Oly6o.
